The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

A cross-linked copolymer is provided, including at least repeating units of poly(alkylene oxide) and at least repeating units of lithium polystyrene-sulfonyl(trifluoromethylsulfonyl)imide (PSTFSILi), as well as the use of such a cross-linked copolymer for preparing a solid polymer electrolyte, a solid polymer electrolyte having the cross-linked copolymer, and a battery, for example a lithium metal polymer (LMP) battery, including the solid polymer electrolyte.

The present invention discloses a polyether derivative and a preparation method therefor. The polyether derivative is:

##STR00001##

the polyether derivative of the present invention has a functional group introduced into the polyether chain, such that the derivative has an ether bond, an ester group, an amino group, a heteroatom, and other groups, enabling the derivative to have various functions such as anti-oxidation, anti-wear functionality, and anti-rust functionality, either without requiring additional additives or requiring fewer additional additives used to make up for the lack of base oil functions.

The subject matter of this invention relates to hydrogel compositions and, more particularly, to hydrogel compositions comprising block copolymers (BCPs) capable of self-assembly into nanoparticles for the delivery and controlled release of therapeutic cargos.

The present invention provides a surfactant having a formula selected from the group consisting of: B—((X).sub.x—(CH.sub.2).sub.a-A).sub.n(VI), (A-(CH.sub.2).sub.a—(X).sub.x—B—(X).sub.x—(CH.sub.2).sub.a-A).sub.n (IV), (A-(CH.sub.2).sub.a—(X).sub.x—B).sub.n (V), and (B).sub.n—(X).sub.x—(CH.sub.2).sub.a-A (VII), wherein A is a perfluoropolyether; a is a positive integer; X is either a covalent bond or a linking group; x is a positive integer; B is a polyalkylene oxide unit; n is a positive integer greater than 1 and, in compounds comprising more than one A, B, X, a and x, each may be the same or different. The present invention also relates to methods of making such surfactants, uses of such surfactants and emulsions comprising such surfactants.

An aqueous dispersion including a polymer having a 2-oxazoline group; and a surfactant, the surfactant containing a sulfuric acid ester compound represented by the following Chemical Formula (S):

R.sup.1—O—(R.sup.2O)nSO.sub.3X  (S)

wherein R.sup.1 represents an aliphatic hydrocarbon group having 8 to 20 carbon atoms; R.sup.2 represents an alkylene group having 2 to 4 carbon atoms; n represents 2 to 15; and X represents a monovalent cation.

The subject matter described herein relates to methods for polymer xanthylation and the xanthylated polymers produced by such methods. Subsequent replacement of the xanthylate moiety allows facile entry into functionalized polymers.

Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.